Table 2.
Classification of renal biopsy samples at baseline and 24 months of treatment according to Banff 2007 classification (23)
| Variable | Baseline, n (%) | 24 mo, n (%) |
|---|---|---|
| Placebo (n=10) | ||
| IF/TA | ||
| Grade I | 9 (90) | 6 (60) |
| Grade II | 0 | 3 (30) |
| Grade III | 1 (10) | 1 (10) |
| C4d staining | ||
| C4d0 | 10 (100) | 9 (90) |
| C4d1 | 0 | 0 |
| C4d2 | 0 | 1 (10) |
| C4d3 | 0 | 0 |
| Total inflammation | ||
| ti1 | 3 (30) | 3 (30) |
| ti2 | 0 | 0 |
| Eplerenone (n=13) | ||
| IF/TA | ||
| Grade I | 12 (92) | 10 (77) |
| Grade II | 1 (8) | 2 (15) |
| Grade III | 0 | 1 (8) |
| C4d staining | ||
| C4d0 | 13 (100) | 9 (69) |
| C4d1 | 0 | 0 |
| C4d2 | 0 | 3 (23) |
| C4d3 | 0 | 1 (8) |
| Total inflammation | ||
| ti1 | 5 (38.4) | 2 (15.3) |
| ti2 | 1 (8) | 1 (8) |
IFTA Grade I, <25% cortical area; II, 26%–50%; III, >50%. C4d staining, C4d0: negative, 0% biopsy sample; C4d1: minimal detection 1 <10%; C4d2: positive focal 10%–50%; C4d3 positive diffuse >50%. Scoring of total inflammation (ti) of renal allograft, ti1: 10%–25% of parenchyma inflamed, and ti2: 26%–50%. IF/TA, interstitial fibrosis/tubular atrophy.